Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Machine learning models in electronic health records can outperform conventional survival models for predicting patient mortality in coronary artery disease.

Steele AJ, Denaxas SC, Shah AD, Hemingway H, Luscombe NM.

PLoS One. 2018 Aug 31;13(8):e0202344. doi: 10.1371/journal.pone.0202344. eCollection 2018.

2.

Roring ahead with DOCK2.

Steele AJ.

Blood. 2018 Jul 12;132(2):115-116. doi: 10.1182/blood-2018-05-848382. No abstract available.

PMID:
30002044
3.

Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation.

Johnston HE, Carter MJ, Larrayoz M, Clarke J, Garbis SD, Oscier D, Strefford JC, Steele AJ, Walewska R, Cragg MS.

Mol Cell Proteomics. 2018 Apr;17(4):776-791. doi: 10.1074/mcp.RA117.000539. Epub 2018 Jan 24.

PMID:
29367434
4.

Mycobacterium tuberculosis subverts negative regulatory pathways in human macrophages to drive immunopathology.

Brace PT, Tezera LB, Bielecka MK, Mellows T, Garay D, Tian S, Rand L, Green J, Jogai S, Steele AJ, Millar TM, Sanchez-Elsner T, Friedland JS, Proud CG, Elkington PT.

PLoS Pathog. 2017 Jun 1;13(6):e1006367. doi: 10.1371/journal.ppat.1006367. eCollection 2017 Jun.

5.

STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Dahal LN, Dou L, Hussain K, Liu R, Earley A, Cox KL, Murinello S, Tracy I, Forconi F, Steele AJ, Duriez PJ, Gomez-Nicola D, Teeling JL, Glennie MJ, Cragg MS, Beers SA.

Cancer Res. 2017 Jul 1;77(13):3619-3631. doi: 10.1158/0008-5472.CAN-16-2784. Epub 2017 May 16.

6.

Releasing the brakes on BTK-targeting miRNA.

Blunt MD, Steele AJ.

Blood. 2016 Dec 29;128(26):3023-3024. doi: 10.1182/blood-2016-11-748145. No abstract available.

7.

IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.

Drennan S, D'Avola A, Gao Y, Weigel C, Chrysostomou E, Steele AJ, Zenz T, Plass C, Johnson PW, Williams AP, Packham G, Stevenson FK, Oakes CC, Forconi F.

Leukemia. 2017 Aug;31(8):1686-1694. doi: 10.1038/leu.2016.356. Epub 2016 Nov 28.

PMID:
27890932
8.

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.

Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, Gibson J, Wang J, Ljungström V, Wojdacz TK, Chaplin T, Roghanian A, Davis Z, Parker A, Tausch E, Ntoufa S, Ramos S, Robbe P, Alsolami R, Steele AJ, Packham G, Rodríguez-Vicente AE, Brown L, McNicholl F, Forconi F, Pettitt A, Hillmen P, Dyer M, Cragg MS, Chelala C, Oakes CC, Rosenquist R, Stamatopoulos K, Stilgenbauer S, Knight S, Schuh A, Oscier DG, Strefford JC.

Leukemia. 2016 Nov;30(11):2179-2186. doi: 10.1038/leu.2016.134. Epub 2016 May 20.

9.

Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial.

Larrayoz M, Rose-Zerilli MJ, Kadalayil L, Parker H, Blakemore S, Forster J, Davis Z, Steele AJ, Collins A, Else M, Catovsky D, Oscier DG, Strefford JC.

Leukemia. 2017 Feb;31(2):510-514. doi: 10.1038/leu.2016.298. Epub 2016 Oct 26. No abstract available.

10.

Bimetallic MOFs (H3O)x[Cu(MF6)(pyrazine)2]·(4 - x)H2O (M = V4+, x = 0; M = Ga3+, x = 1): co-existence of ordered and disordered quantum spins in the V4+ system.

Manson JL, Schlueter JA, Garrett KE, Goddard PA, Lancaster T, Möller JS, Blundell SJ, Steele AJ, Franke I, Pratt FL, Singleton J, Bendix J, Lapidus SH, Uhlarz M, Ayala-Valenzuela O, McDonald RD, Gurak M, Baines C.

Chem Commun (Camb). 2016 Oct 18;52(85):12653-12656.

PMID:
27713934
11.

The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, Parnell J, Smith LD, Davies A, Johnson PWM, Conley PB, Pandey A, Strefford JC, Stevenson FK, Packham G, Forconi F, Coffey GP, Burger JA, Steele AJ.

Clin Cancer Res. 2017 May 1;23(9):2313-2324. doi: 10.1158/1078-0432.CCR-16-1662. Epub 2016 Oct 3.

12.

PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells.

Yeomans A, Lemm E, Wilmore S, Cavell BE, Valle-Argos B, Krysov S, Hidalgo MS, Leonard E, Willis AE, Forconi F, Stevenson FK, Steele AJ, Coldwell MJ, Packham G.

Oncotarget. 2016 Nov 15;7(46):74807-74819. doi: 10.18632/oncotarget.11655.

13.

To BH3 profile or not to BH3 profile.

Blunt MD, Steele AJ.

Blood. 2016 Jun 23;127(25):3111-2. doi: 10.1182/blood-2016-04-711762. No abstract available.

14.

Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL.

D'Avola A, Drennan S, Tracy I, Henderson I, Chiecchio L, Larrayoz M, Rose-Zerilli M, Strefford J, Plass C, Johnson PW, Steele AJ, Packham G, Stevenson FK, Oakes CC, Forconi F.

Blood. 2016 Aug 11;128(6):816-26. doi: 10.1182/blood-2016-03-707786. Epub 2016 Jun 14.

15.

IL-4 enhances expression and function of surface IgM in CLL cells.

Aguilar-Hernandez MM, Blunt MD, Dobson R, Yeomans A, Thirdborough S, Larrayoz M, Smith LD, Linley A, Strefford JC, Davies A, Johnson PM, Savelyeva N, Cragg MS, Forconi F, Packham G, Stevenson FK, Steele AJ.

Blood. 2016 Jun 16;127(24):3015-25. doi: 10.1182/blood-2015-11-682906. Epub 2016 Mar 21.

16.

Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease.

Rose-Zerilli MJ, Gibson J, Wang J, Tapper W, Davis Z, Parker H, Larrayoz M, McCarthy H, Walewska R, Forster J, Gardiner A, Steele AJ, Chelala C, Ennis S, Collins A, Oakes CC, Oscier DG, Strefford JC.

Leukemia. 2016 Jun;30(6):1301-10. doi: 10.1038/leu.2016.10. Epub 2016 Feb 5.

17.

Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia.

Blunt MD, Steele AJ.

Leuk Res Rep. 2015 Sep 18;4(2):60-3. doi: 10.1016/j.lrr.2015.09.001. eCollection 2015. Review.

18.

Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.

Yeomans A, Thirdborough SM, Valle-Argos B, Linley A, Krysov S, Hidalgo MS, Leonard E, Ishfaq M, Wagner SD, Willis AE, Steele AJ, Stevenson FK, Forconi F, Coldwell MJ, Packham G.

Blood. 2016 Jan 28;127(4):449-57. doi: 10.1182/blood-2015-07-660969. Epub 2015 Oct 21.

19.

The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.

Larrayoz M, Blakemore SJ, Dobson RC, Blunt MD, Rose-Zerilli MJ, Walewska R, Duncombe A, Oscier D, Koide K, Forconi F, Packham G, Yoshida M, Cragg MS, Strefford JC, Steele AJ.

Leukemia. 2016 Feb;30(2):351-60. doi: 10.1038/leu.2015.286. Epub 2015 Oct 21.

PMID:
26488112
20.

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Strefford JC, Kadalayil L, Forster J, Rose-Zerilli MJ, Parker A, Lin TT, Heppel N, Norris K, Gardiner A, Davies Z, Gonzalez de Castro D, Else M, Steele AJ, Parker H, Stankovic T, Pepper C, Fegan C, Baird D, Collins A, Catovsky D, Oscier DG.

Leukemia. 2015 Dec;29(12):2411-4. doi: 10.1038/leu.2015.217. Epub 2015 Aug 10. No abstract available.

21.

A gene-expression-based neural code for food abundance that modulates lifespan.

Entchev EV, Patel DS, Zhan M, Steele AJ, Lu H, Ch'ng Q.

Elife. 2015 May 12;4:e06259. doi: 10.7554/eLife.06259.

22.

The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model.

Blunt MD, Carter MJ, Larrayoz M, Smith LD, Aguilar-Hernandez M, Cox KL, Tipton T, Reynolds M, Murphy S, Lemm E, Dias S, Duncombe A, Strefford JC, Johnson PW, Forconi F, Stevenson FK, Packham G, Cragg MS, Steele AJ.

Blood. 2015 Jun 25;125(26):4032-41. doi: 10.1182/blood-2014-11-610329. Epub 2015 May 8.

23.

Higher levels of reactive oxygen species are associated with anergy in chronic lymphocytic leukemia.

Linley A, Valle-Argos B, Steele AJ, Stevenson FK, Forconi F, Packham G.

Haematologica. 2015 Jul;100(7):e265-8. doi: 10.3324/haematol.2014.120824. Epub 2015 Mar 6. No abstract available.

24.

Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Winkelmann N, Rose-Zerilli M, Forster J, Parry M, Parker A, Gardiner A, Davies Z, Steele AJ, Parker H, Cross NC, Oscier DG, Strefford JC.

Haematologica. 2015 Jun;100(6):e237-9. doi: 10.3324/haematol.2014.120238. Epub 2015 Feb 20. No abstract available.

25.

Rewiring of sIgM-Mediated Intracellular Signaling through the CD180 Toll-like Receptor.

Porakishvili N, Vispute K, Steele AJ, Rajakaruna N, Kulikova N, Tsertsvadze T, Nathwani A, Damle RN, Clark EA, Rai KR, Chiorazzi N, Lydyard PM.

Mol Med. 2015 Apr;21(1):46-57. doi: 10.2119/molmed.2014.00265. Epub 2015 Jan 14.

26.

PI3K in CLL: are 2 isoforms better than 1?

Steele AJ.

Blood. 2014 Dec 4;124(24):3508-10. doi: 10.1182/blood-2014-10-605089. No abstract available.

27.

Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.

Krysov S, Steele AJ, Coelho V, Linley A, Sanchez Hidalgo M, Carter M, Potter KN, Kennedy B, Duncombe AS, Ashton-Key M, Forconi F, Stevenson FK, Packham G.

Blood. 2014 Nov 13;124(20):3101-9. doi: 10.1182/blood-2014-04-567198. Epub 2014 Aug 28.

28.

Tumour cells expressing single VEGF isoforms display distinct growth, survival and migration characteristics.

Kanthou C, Dachs GU, Lefley DV, Steele AJ, Coralli-Foxon C, Harris S, Greco O, Dos Santos SA, Reyes-Aldasoro CC, English WR, Tozer GM.

PLoS One. 2014 Aug 13;9(8):e104015. doi: 10.1371/journal.pone.0104015. eCollection 2014.

29.

The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy.

Packham G, Krysov S, Allen A, Savelyeva N, Steele AJ, Forconi F, Stevenson FK.

Haematologica. 2014 Jul;99(7):1138-48. doi: 10.3324/haematol.2013.098384. Review.

30.

ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Rose-Zerilli MJ, Forster J, Parker H, Parker A, Rodríguez AE, Chaplin T, Gardiner A, Steele AJ, Collins A, Young BD, Skowronska A, Catovsky D, Stankovic T, Oscier DG, Strefford JC.

Haematologica. 2014 Apr;99(4):736-42. doi: 10.3324/haematol.2013.098574. Epub 2014 Feb 28.

31.

Dimensionality selection in a molecule-based magnet.

Goddard PA, Manson JL, Singleton J, Franke I, Lancaster T, Steele AJ, Blundell SJ, Baines C, Pratt FL, McDonald RD, Ayala-Valenzuela OE, Corbey JF, Southerland HI, Sengupta P, Schlueter JA.

Phys Rev Lett. 2012 Feb 17;108(7):077208. Epub 2012 Feb 17.

PMID:
22401252
32.

Importance of halogen···halogen contacts for the structural and magnetic properties of CuX2(pyrazine-N,N′-dioxide)(H2O)2 (X = Cl and Br).

Schlueter JA, Park H, Halder GJ, Armand WR, Dunmars C, Chapman KW, Manson JL, Singleton J, McDonald R, Plonczak A, Kang J, Lee C, Whangbo MH, Lancaster T, Steele AJ, Franke I, Wright JD, Blundell SJ, Pratt FL, deGeorge J, Turnbull MM, Landee CP.

Inorg Chem. 2012 Feb 20;51(4):2121-9. doi: 10.1021/ic201924q. Epub 2012 Feb 1.

PMID:
22296451
33.

Ag(nic)2 (nic = nicotinate): a spin-canted quasi-2D antiferromagnet composed of square-planar S = 1/2 Ag(II) ions.

Manson JL, Woods TJ, Lapidus SH, Stephens PW, Southerland HI, Zapf VS, Singleton J, Goddard PA, Lancaster T, Steele AJ, Blundell SJ.

Inorg Chem. 2012 Feb 20;51(4):1989-91. doi: 10.1021/ic202600n. Epub 2012 Jan 27.

PMID:
22283606
34.

B-cell receptor signaling in chronic lymphocytic leukemia.

Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G.

Blood. 2011 Oct 20;118(16):4313-20. doi: 10.1182/blood-2011-06-338855. Epub 2011 Aug 3.

35.

Structural, electronic, and magnetic properties of quasi-1D quantum magnets [Ni(HF2)(pyz)2]X (pyz = pyrazine; X = PF6(-), SbF6(-)) exhibiting Ni-FHF-Ni and Ni-pyz-Ni spin interactions.

Manson JL, Lapidus SH, Stephens PW, Peterson PK, Carreiro KE, Southerland HI, Lancaster T, Blundell SJ, Steele AJ, Goddard PA, Pratt FL, Singleton J, Kohama Y, McDonald RD, Del Sesto RE, Smith NA, Bendix J, Zvyagin SA, Kang J, Lee C, Whangbo MH, Zapf VS, Plonczak A.

Inorg Chem. 2011 Jul 4;50(13):5990-6009. doi: 10.1021/ic102532h. Epub 2011 May 20.

PMID:
21598910
36.

p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.

Wickremasinghe RG, Prentice AG, Steele AJ.

Leukemia. 2011 Sep;25(9):1400-7. doi: 10.1038/leu.2011.103. Epub 2011 May 13. Review.

PMID:
21566651
37.

Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets.

Wickremasinghe RG, Prentice AG, Steele AJ.

Br J Haematol. 2011 Jun;153(5):545-56. doi: 10.1111/j.1365-2141.2011.08676.x. Epub 2011 Apr 18. Review.

PMID:
21501136
38.

Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights.

Patel B, Dey A, Ghorani E, Kumar S, Malam Y, Rai L, Steele AJ, Thomson J, Wickremasinghe RG, Zhang Y, Castleton AZ, Fielding AK.

Mol Ther. 2011 Jun;19(6):1034-40. doi: 10.1038/mt.2011.44. Epub 2011 Mar 22.

39.

[Cu(HF2)2 (pyrazine)]n: a rectangular antiferromagnetic lattice with a spin exchange path made up of two different FHF- bridges.

Manson JL, Warter ML, Schlueter JA, Lancaster T, Steele AJ, Blundell SJ, Pratt FL, Singleton J, McDonald RD, Lee C, Whangbo MH, Plonczak A.

Angew Chem Int Ed Engl. 2011 Feb 11;50(7):1573-6. doi: 10.1002/anie.201006653. Epub 2011 Jan 14. No abstract available.

PMID:
21308907
40.

The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment.

Steele AJ, Prentice AG, Cwynarski K, Hoffbrand AV, Hart SM, Lowdell MW, Samuel ER, Wickremasinghe RG.

Blood. 2010 Nov 25;116(22):4569-77. doi: 10.1182/blood-2009-09-245811. Epub 2010 Aug 17.

41.

Compositional control of the superconducting properties of LiFeAs.

Pitcher MJ, Lancaster T, Wright JD, Franke I, Steele AJ, Baker PJ, Pratt FL, Thomas WT, Parker DR, Blundell SJ, Clarke SJ.

J Am Chem Soc. 2010 Aug 4;132(30):10467-76. doi: 10.1021/ja103196c.

PMID:
20662524
42.

Control of the competition between a magnetic phase and a superconducting phase in cobalt-doped and nickel-doped NaFeAs using electron count.

Parker DR, Smith MJ, Lancaster T, Steele AJ, Franke I, Baker PJ, Pratt FL, Pitcher MJ, Blundell SJ, Clarke SJ.

Phys Rev Lett. 2010 Feb 5;104(5):057007. Epub 2010 Feb 5.

PMID:
20366791
43.

2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.

Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Lowdell MW, Samuel ER, North JM, Nacheva EP, Chanalaris A, Kottaridis P, Cwynarski K, Wickremasinghe RG.

Blood. 2009 Aug 6;114(6):1217-25. doi: 10.1182/blood-2008-11-190587. Epub 2009 Jun 10.

44.

Characterization of the antiferromagnetism in Ag(pyz)2(S2O8) (pyz = pyrazine) with a two-dimensional square lattice of Ag2+ ions.

Manson JL, Stone KH, Southerland HI, Lancaster T, Steele AJ, Blundell SJ, Pratt FL, Baker PJ, McDonald RD, Sengupta P, Singleton J, Goddard PA, Lee C, Whangbo MH, Warter MM, Mielke CH, Stephens PW.

J Am Chem Soc. 2009 Apr 8;131(13):4590-1. doi: 10.1021/ja9005223.

PMID:
19334770
45.

p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.

Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Nacheva EP, Howard-Reeves JD, Duke VM, Kottaridis PD, Cwynarski K, Vassilev LT, Wickremasinghe RG.

Blood. 2008 Nov 1;112(9):3827-34. doi: 10.1182/blood-2008-05-156380. Epub 2008 Aug 5.

46.

Collective behavior of stabilized reaction-diffusion waves.

Steele AJ, Tinsley M, Showalter K.

Chaos. 2008 Jun;18(2):026108. doi: 10.1063/1.2900386.

PMID:
18601510
47.

Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression.

Dachs GU, Steele AJ, Coralli C, Kanthou C, Brooks AC, Gunningham SP, Currie MJ, Watson AI, Robinson BA, Tozer GM.

BMC Cancer. 2006 Dec 7;6:280.

48.

The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro.

Steele AJ, Jones DT, Ganeshaguru K, Duke VM, Yogashangary BC, North JM, Lowdell MW, Kottaridis PD, Mehta AB, Prentice AG, Hoffbrand AV, Wickremasinghe RG.

Leukemia. 2006 Jun;20(6):1073-9.

PMID:
16628188
49.

Spatiotemporal dynamics of networks of excitable nodes.

Steele AJ, Tinsley M, Showalter K.

Chaos. 2006 Mar;16(1):015110.

PMID:
16599776
50.

Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide.

Marks AJ, Cooper MS, Anderson RJ, Orchard KH, Hale G, North JM, Ganeshaguru K, Steele AJ, Mehta AB, Lowdell MW, Wickremasinghe RG.

Cancer Res. 2005 Mar 15;65(6):2373-7.

Supplemental Content

Loading ...
Support Center